TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TEVA - US8816242098 - ADR
31.21 USD
+0.86 (+2.83%)
31.21 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to TEVA. TEVA was compared to 192 industry peers in the Pharmaceuticals industry. TEVA scores excellent on profitability, but there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TEVA was profitable.
TEVA had a positive operating cash flow in the past year.
In the past 5 years TEVA reported 4 times negative net income.
TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.79%, TEVA belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
The Return On Equity of TEVA (9.82%) is better than 84.90% of its industry peers.
TEVA's Return On Invested Capital of 10.63% is amongst the best of the industry. TEVA outperforms 90.10% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for TEVA is below the industry average of 12.85%.
The 3 year average ROIC (9.12%) for TEVA is below the current ROIC(10.63%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROIC | 10.63% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA has a better Profit Margin (4.24%) than 81.25% of its industry peers.
TEVA has a better Operating Margin (22.76%) than 90.10% of its industry peers.
In the last couple of years the Operating Margin of TEVA has grown nicely.
TEVA has a Gross Margin of 51.33%. This is in the better half of the industry: TEVA outperforms 64.06% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TEVA is still creating some value.
TEVA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TEVA has been increased compared to 5 years ago.
Compared to 1 year ago, TEVA has an improved debt to assets ratio.
2.2 Solvency
TEVA has an Altman-Z score of 0.91. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.91, TEVA is in line with its industry, outperforming 51.04% of the companies in the same industry.
The Debt to FCF ratio of TEVA is 29.05, which is on the high side as it means it would take TEVA, 29.05 years of fcf income to pay off all of its debts.
TEVA's Debt to FCF ratio of 29.05 is fine compared to the rest of the industry. TEVA outperforms 74.48% of its industry peers.
A Debt/Equity ratio of 2.32 is on the high side and indicates that TEVA has dependencies on debt financing.
TEVA has a Debt to Equity ratio of 2.32. This is in the lower half of the industry: TEVA underperforms 78.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Altman-Z | 0.91 |
ROIC/WACC1.29
WACC8.24%
2.3 Liquidity
A Current Ratio of 1.11 indicates that TEVA should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.11, TEVA is doing worse than 82.29% of the companies in the same industry.
A Quick Ratio of 0.82 indicates that TEVA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.82, TEVA is doing worse than 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
TEVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.96%.
The Earnings Per Share has been decreasing by -1.18% on average over the past years.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 0.02% in the last year.
The Revenue has been decreasing by -0.41% on average over the past years.
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
3.2 Future
The Earnings Per Share is expected to grow by 8.13% on average over the next years. This is quite good.
TEVA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.76% yearly.
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.52 indicates a reasonable valuation of TEVA.
Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.39, TEVA is valued rather cheaply.
With a Price/Forward Earnings ratio of 11.09, the valuation of TEVA can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 85.94% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TEVA to the average of the S&P500 Index (23.84), we can say TEVA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.52 | ||
| Fwd PE | 11.09 |
4.2 Price Multiples
TEVA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TEVA is cheaper than 86.98% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TEVA is valued a bit cheaper than 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.94 | ||
| EV/EBITDA | 10.23 |
4.3 Compensation for Growth
TEVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)1.35
PEG (5Y)N/A
EPS Next 2Y5.56%
EPS Next 3Y8.13%
5. Dividend
5.1 Amount
No dividends for TEVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
31.21
+0.86 (+2.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.54%
Inst Owner Change-9.16%
Ins Owners0.43%
Ins Owner Change-1.57%
Market Cap35.80B
Revenue(TTM)16.78B
Net Income(TTM)712.00M
Analysts82.86
Price Target0.11 (-99.65%)
Short Float %4.06%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.58%
Min EPS beat(2)4.65%
Max EPS beat(2)16.51%
EPS beat(4)4
Avg EPS beat(4)7.25%
Min EPS beat(4)2.01%
Max EPS beat(4)16.51%
EPS beat(8)7
Avg EPS beat(8)7.06%
EPS beat(12)8
Avg EPS beat(12)1.63%
EPS beat(16)10
Avg EPS beat(16)1.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)0.9%
Revenue beat(4)2
Avg Revenue beat(4)-1.98%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)0.9%
Revenue beat(8)5
Avg Revenue beat(8)0.57%
Revenue beat(12)7
Avg Revenue beat(12)0.43%
Revenue beat(16)7
Avg Revenue beat(16)-1.36%
PT rev (1m)93.03%
PT rev (3m)93.38%
EPS NQ rev (1m)-1.18%
EPS NQ rev (3m)-3.48%
EPS NY rev (1m)3.17%
EPS NY rev (3m)3.17%
Revenue NQ rev (1m)-0.6%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.49%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.52 | ||
| Fwd PE | 11.09 | ||
| P/S | 2.13 | ||
| P/FCF | 61.94 | ||
| P/OCF | 33.59 | ||
| P/B | 4.94 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.23 |
EPS(TTM)2.71
EY8.68%
EPS(NY)2.82
Fwd EY9.02%
FCF(TTM)0.5
FCFY1.61%
OCF(TTM)0.93
OCFY2.98%
SpS14.62
BVpS6.32
TBVpS-11.01
PEG (NY)1.35
PEG (5Y)N/A
Graham Number19.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.79% | ||
| ROE | 9.82% | ||
| ROCE | 13.46% | ||
| ROIC | 10.63% | ||
| ROICexc | 11.52% | ||
| ROICexgc | 47.85% | ||
| OM | 22.76% | ||
| PM (TTM) | 4.24% | ||
| GM | 51.33% | ||
| FCFM | 3.45% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score7
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.32 | ||
| Debt/FCF | 29.05 | ||
| Debt/EBITDA | 3.48 | ||
| Cap/Depr | 48.27% | ||
| Cap/Sales | 2.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 22.08% | ||
| Profit Quality | 81.18% | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 0.91 |
F-Score7
WACC8.24%
ROIC/WACC1.29
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.96%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y8.54%
EPS Next 2Y5.56%
EPS Next 3Y8.13%
EPS Next 5YN/A
Revenue 1Y (TTM)0.02%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%3.42%
Revenue Next Year3.29%
Revenue Next 2Y1.8%
Revenue Next 3Y1.76%
Revenue Next 5YN/A
EBIT growth 1Y-3.39%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.41%
EBIT Next 3Y9.92%
EBIT Next 5YN/A
FCF growth 1Y-4.93%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-7.87%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.52 and the Price/Book (PB) ratio is 4.94.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.